drugset
drugset / Trial / NCT03396484

Methyldopa for Reduction of DQ8 Antigen Presentation in At-Risk Subjects for Type 1 Diabetes

NCT03396484 ↗

Phase 2 Withdrawn National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
RandomizedCrossoverDouble-blindPrevention

Summary

A study is to see if methyldopa can change the immune system's attack on insulin producing cells in people at early stages of type 1 diabetes.

Timeline

Start
2020-09
Primary completion
2022-03
Completion
2022-03

Outcome

Outcome not reported

Stopped: “Study not begun due to continued laboratory work on the feasibility of outcome measures.”

Drugs

EvaluationDrugModalityDoseRoute
Subject Methyldopa Unknown 500 mg Oral

Indications

type 1 diabetes mellitus